Cargando…

S214: DISEASE-MODIFYING ACTIVITY OF NAVTEMADLIN (NVTM) CORRELATED WITH SURVIVAL OUTCOMES IN JANUS KINASE INHIBITOR (JAKI) RELAPSED OR REFRACTORY (R/R) MYELOFIBROSIS (MF) PATIENTS (PTS)

Detalles Bibliográficos
Autores principales:	Vachhani, Pankit, Perkins, Andrew, Mascarenhas, John, Al-Ali, Haifa Kathrin, Kiladjian, Jean-Jacques, Cerquozzi, Sonia, Dybko, Jaroslaw, Delgado, Regina Garcia, Rivas, Jesus Hernández, Hebart, Holger, Huang, Zhuying, Krejsa, Cecile, Qamoos, Hope, Mcgreivy, Jesse, Rothbaum, Wayne P., Verstovsek, Srdan, Vannucchi, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Oral Sessions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428410/ http://dx.doi.org/10.1097/01.HS9.0000967768.05521.ca

Ejemplares similares

P991: ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) POTENTIATES APOPTOSIS IN MYELOBLASTS FROM PATIENTS (PTS) WITH MYELOFIBROSIS (MF)
por: Clevenger, Tracy, et al.
Publicado: (2023)

S210: AN OPEN-LABEL, GLOBAL, PHASE (PH) 1B/2 STUDY ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH PRIMARY OR SECONDARY MYELOFIBROSIS (MF) WHO HAVE A SUBOPTIMAL RESPONSE TO RUX
por: Mascarenhas, John, et al.
Publicado: (2023)

PB2198: TRIAL IN PROGRESS: AN OPEN-LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL-895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF)
por: Palandri, Francesca, et al.
Publicado: (2023)

P1038: TL-895, A FIRST-IN-CLASS, COVALENT BRUTON TYROSINE KINASE INHIBITOR (BTKI) FOR THE TREATMENT OF MYELOFIBROSIS (MF) PATIENTS (PTS) WITH SEVERE THROMBOCYTOPENIA (PLATELETS (PLTS) <50 K/UL)
por: Loschi, Michael, et al.
Publicado: (2023)

Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis
por: Gupta, Vikas, et al.
Publicado: (2023)

MF management
por: Bose, Prithviraj, et al.
Publicado: (2019)

P1055: BROMODOMAIN AND EXTRA-TERMINAL (BET) INHIBITOR INCB057643 (LIMBER-103) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MYELOFIBROSIS (R/R MF) AND OTHER ADVANCED MYELOID NEOPLASMS: A PHASE 1 STUDY
por: Watts, Justin M., et al.
Publicado: (2023)

P625: A PHASE 1B/2 STUDY OF NAVTEMADLIN COMBINED WITH ACALABRUTINIB IN BTK INHIBITOR NAÏVE PATIENTS WITH RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
por: Byrd, John C., et al.
Publicado: (2023)

P15 JAKi of all trades
por: Watkins, Clara, et al.
Publicado: (2023)

P1020: SELINEXOR (SEL) PLUS RUXOLITINIB (RUX) IN JAK INHIBITOR (JAKI) TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS: UPDATED RESULTS FROM XPORT-MF-034
por: Ali, Haris, et al.
Publicado: (2023)

Pharmacokinetics and Macrophage Inhibitory Cytokine‐1 Pharmacodynamics of the Murine Double Minute 2 Inhibitor, Navtemadlin (KRT‐232) in Fed and Fasted Healthy Subjects
por: Wong, Shekman, et al.
Publicado: (2022)

S207: NAVTEMADLIN, AN ORAL MDM2 INHIBITOR, ELIMINATES MYELOPROLIFERATIVE NEOPLASM-BLAST PHASE (MPN-BP) INITIATING CELLS AND PROLONGS LEUKEMIA-FREE SURVIVAL (LFS) IN AN MPN-BP PDX MODEL
por: Wang, Xiaoli, et al.
Publicado: (2023)

P1006: CHARACTERIZATION OF TL-895: A NOVEL BRUTON TYROSINE KINASE INHIBITOR (BTKI) IN CLINICAL DEVELOPMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND MYELOFIBROSIS (MF)
por: Gulrajani, Michael, et al.
Publicado: (2023)

Ruxolitinib: a targeted treatment option for patients with polycythemia vera
por: Vaddi, Kris, et al.
Publicado: (2016)

Hi-JAKi-ng Synovial Fibroblasts in Inflammatory Arthritis With JAK Inhibitors
por: Burja, Blaž, et al.
Publicado: (2020)

S167: EFFICACY AND SAFETY OF LUSPATERCEPT FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH MYELOFIBROSIS: RESULTS FROM THE ACE-536-MF-001 STUDY
por: Gerds, Aaron T., et al.
Publicado: (2023)

The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
por: Ingelshed, Katrine, et al.
Publicado: (2022)

Isolated Gastric Myeloid Sarcoma: A Case Report and Review of the Literature
por: Vachhani, Pankit, et al.
Publicado: (2014)

Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date
por: Vachhani, Pankit, et al.
Publicado: (2016)

PB2183: TRANSFUSION-RELATED COST OFFSETS AND TIME BURDEN IN PATIENTS WITH MYELOFIBROSIS (MF) TREATED WITH MOMELOTINIB (MMB) VS DANAZOL (DAN)
por: Masarova, Lucia, et al.
Publicado: (2023)

OA20 Combining B cell depletion and JAKi for difficult-to-treat rheumatoid arthritis
por: Lee, Sook Yan, et al.
Publicado: (2023)

How the COVID-19 Pandemic Reshaped the Management of Leukemia and Affected Patient Outcomes
por: Sharafeldin, Noha, et al.
Publicado: (2022)

Skywave Detection and Mitigation for the MF R-Mode Continuously Operating Reference Station
por: Son, Pyo-Woong, et al.
Publicado: (2023)

Case report: JAKi and TNFi dual therapy is a potential treatment strategy for difficult-to-treat rheumatoid arthritis
por: Chen, Jing-Wen, et al.
Publicado: (2022)

JAKi Salvage Therapy Followed by Curative Cord Blood Transplantation in a XIAP-Deficient Infant with Relapsing HLH
por: Maccari, Maria Elena, et al.
Publicado: (2023)

Remission of Severe, Relapsed, and Refractory TTP after Multiple Cycles of Bortezomib
por: Pandey, Manu R., et al.
Publicado: (2017)

Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression
por: Verstovsek, Srdan
Publicado: (2013)

How I manage anemia related to myelofibrosis and its treatment regimens
por: Verstovsek, Srdan
Publicado: (2023)

P1162: ZANUBRUTINIB IN OLDER PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): SUBGROUP ANALYSIS OF THE MAGNOLIA STUDY
por: Opat, S., et al.
Publicado: (2022)

TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD
por: Regierer, Anne Constanze, et al.
Publicado: (2021)

The DeoR-type transcriptional regulator SugR acts as a repressor for genes encoding the phosphoenolpyruvate:sugar phosphotransferase system (PTS) in Corynebacterium glutamicum
por: Gaigalat, Lars, et al.
Publicado: (2007)

All-trans-retinoic-acid and arsenic trioxide induced remission in promyelocytic blast crisis
por: Colvin, Teresa A., et al.
Publicado: (2018)

The Italian scenario, pts 1-2
por: Belloni, L
Publicado: (1987)

PTS: a pharmaceutical target seeker
por: Ding, Peng, et al.
Publicado: (2017)

Ruxolitinib for essential thrombocythemia?
por: Bose, Prithviraj, et al.
Publicado: (2017)

Updates in the management of polycythemia vera and essential thrombocythemia
por: Bose, Prithviraj, et al.
Publicado: (2019)

JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives
por: Bose, Prithviraj, et al.
Publicado: (2020)

Clinical development and management of adverse events associated with FGFR inhibitors
por: Subbiah, Vivek, et al.
Publicado: (2023)

P1042: SAFETY AND TOLERABILITY RESULTS FROM THE PHASE 3B FREEDOM TRIAL OF FEDRATINIB (FEDR), AN ORAL, SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF) PREVIOUSLY TREATED WITH RUXOLITINIB (RUX)
por: Gupta, V., et al.
Publicado: (2022)

Pistia Stratiotes and MF. Malayi
por: Fraser, G.
Publicado: (1938)

Cannot write session to /tmp/vufind_sessions/sess_v734pjgrunm1h25ilsgcsdel2a